Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. hope

HOPE SIGNED

Host Protective Engineering of Cancer Immunity by Targeting the Intracellular Immune Checkpoint NR2F6

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HOPE project word cloud

Explore the words cloud of the HOPE project. It provides you a very rough idea of what is the project "HOPE" about.

mission    inflammation    inseparable    prerequisite    employing    proteomic    pkc    resistance    perturbation    site    strategies    potentially    crispr    lymphocyte    nr2f6    functions    tumours    crossroads    pd    poorly    technologies    first    network    events    adverse    recurrence    node    influence    epidemiologically    startegies    predisposition    host    either    cells    supports    pronged    overcome    risk    progression    successful    microenvironment    latter    prevalent    signalling    prevention    delineate    clinic    initiation    cancer    rendering    biochemical    metastases    checkpoint    cas9    therapeutic    nsclc    clinically    reveal    functional    immune    effector    spread    immunity    reducing    tumour    clinical    oncology    mechanisms    protective    profoundly    immunological    elucidated    complexity    lung    transcriptomic    chronic    combinatorial    prevents    molecular    validate    therapy    experimentally    genetic    team    biological    tools    combination    intrinsic    limitations    screening    generation    inhibitors    preventive    rejecting    organs    cell    anti    signatures    genomic    shown    human    distal    axis    entities   

Project "HOPE" data sheet

The following table provides information about the project.

Coordinator		 MEDIZINISCHE UNIVERSITAT INNSBRUCK 

Organization address
address: CHRISTOPH PROBST PLATZ 1
city: INNSBRUCK
postcode: 6020
website: www.i-med.ac.at

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Austria [AT]
 Total cost 2˙484˙325 €
 EC max contribution 2˙484˙325 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-ADG
 Funding Scheme ERC-ADG
 Starting year 2018
 Duration (year-month-day) from 2018-10-01   to  2023-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEDIZINISCHE UNIVERSITAT INNSBRUCK AT (INNSBRUCK) coordinator 2˙484˙325.00

Map

 Project objective

'Because of its biological complexity, cancer is still poorly understood. Chronic inflammation has been shown, both experimentally and epidemiologically, to be a predisposition to, and also an inseparable aspect of clinically prevalent cancer entities. Therefore, a detailed understanding of both tumour and immune cell functions in cancer progression is a prerequisite for more successful therapeutic startegies. My team was the first to reveal the lymphocyte-intrinsic PKC/NR2F6 axis as an essential signalling node at the crossroads between inflammation and cancer. It is the mission of this project to identify molecular signatures that influence the risk of developing tumours employing established research tools and state-of-the-art genetic, biochemical, proteomic and transcriptomic as well as large scale CRISPR/Cas9 perturbation screening-based functional genomic technologies. Defining this as yet poorly elucidated effector pathway with its profoundly relevant role would enable development of preventive and immune-therapeutic strategies against NSCLC lung cancer and potentially also against other entities. Our three-pronged approach to achieve this goal is to: (i) delineate biological and clinical properties of the immunological PKC/NR2F6 network, (ii) validate NR2F6 as an immune-oncology combination target needed to overcome limitations to 'first generation anti-PD-1 checkpoint inhibitors' rendering T cells capable of rejecting tumours and their metastases at distal organs and (iii) exploit human combinatorial T cell therapy concepts for prevention of immune-related adverse events as well as of tumour recurrence by reducing opportunities for the tumour to develop resistance in the clinic. Insight into the functions of NR2F6 pathway and involved mechanisms is a prerequisite for understanding how the microenvironment at the tumour site either supports tumour growth and spread or prevents tumour initiation and progression, the latter by host-protective cancer immunity.'

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HOPE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HOPE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

KineTic (2020)

New Reagents for Quantifying the Routing and Kinetics of T-cell Activation

Read More  

NEUTRAMENTH (2018)

A redox-neutral process for the cost-efficient and environmentally friendly production of Menthol

Read More  

E-DURA (2018)

Commercialization of novel soft neural interfaces

Read More